SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Djureinovic Dijana)
 

Search: WFRF:(Djureinovic Dijana) > (2023) > Expression of cance...

  • Hikmet Noraddin, FeriaUppsala universitet,Cancerprecisionsmedicin (author)

Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer

  • Article/chapterEnglish2023

Publisher, publication year, extent ...

  • John Wiley & Sons,2023
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-522496
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-522496URI
  • https://doi.org/10.1002/1878-0261.13474DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The antigenic repertoire of tumors is critical for successful anti-cancer immune response and the efficacy of immunotherapy. Cancer-testis antigens (CTAs) are targets of humoral and cellular immune reactions. We aimed to characterize CTA expression in non-small cell lung cancer (NSCLC) in the context of the immune microenvironment. Of 90 CTAs validated by RNA sequencing, eight CTAs (DPEP3, EZHIP, MAGEA4, MAGEB2, MAGEC2, PAGE1, PRAME, and TKTL1) were selected for immunohistochemical profiling in cancer tissues from 328 NSCLC patients. CTA expression was compared with immune cell densities in the tumor environment and with genomic, transcriptomic, and clinical data. Most NSCLC cases (79%) expressed at least one of the analyzed CTAs, and CTA protein expression correlated generally with RNA expression. CTA profiles were associated with immune profiles: high MAGEA4 expression was related to M2 macrophages (CD163) and regulatory T cells (FOXP3), low MAGEA4 was associated with T cells (CD3), and high EZHIP was associated with plasma cell infiltration (adj. P-value < 0.05). None of the CTAs correlated with clinical outcomes. The current study provides a comprehensive evaluation of CTAs and suggests that their association with immune cells may indicate in situ immunogenic effects. The findings support the rationale to harness CTAs as targets for immunotherapy.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Rassy, MarcUppsala universitet,Institutionen för immunologi, genetik och patologi (author)
  • Backman, Max,1987-Uppsala universitet,Cancerimmunterapi(Swepub:uu)maxba655 (author)
  • Méar, LorenUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)lorme902 (author)
  • Mattsson, Johanna Sofia Margareta,1985-Uppsala universitet,Cancerimmunterapi(Swepub:uu)johma961 (author)
  • Djureinovic, DijanaUppsala universitet,Institutionen för immunologi, genetik och patologi,Yale Univ, Sch Med, Dept Med Med Oncol, New Haven, CT USA.(Swepub:uu)dijdj435 (author)
  • Botling, JohanUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)johanbot (author)
  • Brunnström, HansLund Univ, Dept Clin Sci Lund, Div Pathol, Lund, Sweden. (author)
  • Micke, PatrickUppsala universitet,Cancerimmunterapi(Swepub:uu)patmi676 (author)
  • Lindskog, CeciliaUppsala universitet,Cancerprecisionsmedicin(Swepub:uu)cecli129 (author)
  • Uppsala universitetCancerprecisionsmedicin (creator_code:org_t)

Related titles

  • In:Molecular Oncology: John Wiley & Sons17:12, s. 2603-26171574-78911878-0261

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view